Dr. Reddy's Laboratories is a vertically integrated global pharmaceutical company that develops, manufactures, and commercialises generic medicines, branded formulations, APIs, biosimilars, and OTC consumer health products across 50+ countries, with its largest revenue pool in North America, followed by Emerging Markets and India. Semaglutide is the near-term prize, though the latest print cooled as US generics margin compression lingers; priced richly, the market already expects it to land.